I have a diverse background—as a financial journalist, resident physician, mixed martial artist, painter, entrepreneur, chemistry instructor and web developer—that enabled me to pioneer the “Integrated Investing Research” approach.
I provide consulting to clients, both the retail and professional investors. I accurately forecasted many clinical trials, such as the Flint Trials for Intercept, the Ascend Trials for InterMune and the Affinity Trials MannKind, just to name a few. Through Vincata Enterprises, LLC, I helped many clients to unlock substantial values for their investments.
As an expert in biopharmaceutical analysis, I am also more than capable of analyzing any other industries. Though not shown on Seeking Alpha, I have picked an aggregate basket of outperforming stocks.
Investing in biotech is highly risky, but it can be quite rewarding when investors have an edge in data analysis. Physicians who are rigidly scientific tend to lack the analytical prowess of financial experts. Conversely, financiers usually do not possess a physician’s medical expertise. Likewise, scientists are skillful in data analysis; yet they might not be familiar with a physician’s prescribing patterns, which is a requisite to successful biotech investing.
You can visit my website at https://www.retailinvestor360.com for business inquiry.
SkyTides focuses on deep due diligence research of over-hyped stocks, outright stock frauds and public company individuals of questionable character. We use financial analytics, market research, expert opinions, accounting review, litigation review and other investigative methods, to make our case.
Timothy J. Keating is the Chief Executive Officer of BDCA Venture, Inc. (Nasdaq: BDCV), a closed-end fund regulated as a business development company under the Investment Company Act of 1940, as amended (the "1940 Act"). BDCA Venture’s investment objective is to maximize total return by generating current income from debt investments and, to a lesser extent, capital appreciation from equity and equity-related investments. BDCA Venture’s shares are listed on Nasdaq under the ticker symbol BDCV. BDCA Venture is managed by BDCA Venture Adviser, LLC.
Previously, he held senior management positions in the Equity and Equity Derivatives departments of Bear Stearns, Nomura and Kidder, Peabody in both London and New York. He is a 1985 cum laude graduate of Harvard College with an A.B. in economics.
Tim has been widely quoted in the national media, including publications such as the Wall Street Journal, Forbes, Barron’s, Investor’s Business Daily, USA Today, The New York Times, SmartMoney and the Venture Capital Journal. He has been featured on Fox Business’ “After the Closing Bell,” Bloomberg TV’s “Bloomberg West,” CNBC’s “Street Signs,” TheStreet.com and Bloomberg Radio’s “Taking Stock” and “The Hays Advantage.” Tim has also been a guest contributor to Forbes.com, InvestmentNews and Pensions & Investments.
"Wall Street has a few prudent principles; the trouble is that they are always forgotten when they are most needed."
“Doubt is not a pleasant condition, but certainty is absurd.”
"Out of clutter, find simplicity. From discord, find harmony. In the middle of difficulty lies opportunity."
Awarded a 2015 & 2016 "Top 50 Financial Blogger" by TipRanks.com
- Ranked #44 out of 4,408 bloggers (#106 out of 8,174 overall experts) as of 8/18/15
- Ranked #37 out of 5,383 bloggers (#107 out of 9,507 overall experts) as of 8/18/16
- Follow my ongoing coverage on TerraVia (TVIA): http://seekingalpha.com/articles?filters=tvia,kevin-quon
I am the VP of Monetization at Harvest (www.hvst.com). My role here is to ensure that Harvest is maximizing its monetization opportunities while maintaining the highest level of experience for our users, and advertisers.
I am studying for the CFA and have experience working with a team of analysts. I paid off my student loan whilst at university by playing poker although I am now fully retired. I invested the remainder of the funds.
DISCLAIMER: Each article or comment written by this author is intended as general information only, and is not intended to provide specific advice, or due diligence to be relied on. As such, the information presented in any article does not consider any reader’s personal investment objectives or financial situation; therefore, no article makes any personalized recommendations.
Investment strategies or securities mentioned in any article are not suitable for all investors. The risk of loss in trading securities, including options, and futures can be substantial. Options or other transactions could involve complex tax considerations that should be carefully reviewed and considered along with each reader’s personal financial situation and all other relevant risk factors prior to entering into any transaction.
While I believe the information provided in any article is reliable; however, I do not guarantee its accuracy, timelines or completeness. Financial information changes daily and articles are not updated for subsequent changes in financial position or share prices.
Past performance referenced in any article is no guarantee of future performance. You should always consider the risks of investing in the light of your personal circumstances and your due diligence should include consulting with your professional advisor.
The opinions expressed in any of my articles or comments on this website are my own and do not necessarily reflect the views or opinions of any third party. I am not responsible for actions taken, or not taken based the content of this site.
Links to and from websites do not imply any content endorsements. I am not responsible for, nor do I control the content of linked websites which are subject to change without my knowledge or consent.